AZN Earnings & Financial Statements
AstraZeneca PLC
$162.03
+$6.21(+3.99%)
61
Overall
90
Value
30
Tech
65
Quality
Market Cap
$244.56B
Volume
3.22M
52W Range
$153.41 - $212.71
Target Price
$208.66
AZN earnings and financial statements: AstraZeneca PLC's income statement, balance sheet and cash flow statement, annual and quarterly.
AZN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B |
| Cost of revenue | $10.63B | $10.21B | $8.27B | $12.39B | $12.44B |
| Operating income | $13.36B | $10.00B | $8.72B | $3.24B | -$134.00M |
| EBITDA | $19.83B | $17.12B | $13.88B | $9.09B | $5.11B |
| Net income | $10.22B | $7.04B | $5.96B | $2.10B | $112.00M |
| EPS (diluted) | - | $4.50 | $3.81 | $2.11 | $0.08 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $113.58B | $104.03B | $101.12B | $96.48B | $105.36B |
| Total liabilities | $65.85B | $63.16B | $61.95B | $59.42B | $66.08B |
| Shareholders’ equity | $48.67B | $40.79B | $39.14B | $37.04B | $39.27B |
| Cash and equivalents | $5.71B | $5.49B | $1.32B | $1.41B | $1.46B |
| Long-term debt | $26.14B | $27.62B | $23.22B | $23.69B | $28.89B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B |
| Free cash flow | $8.67B | $7.28B | $6.99B | $7.97B | $1.42B |
| Dividends paid | $4.97B | $4.63B | $4.48B | $4.36B | $3.86B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AZN | $162.03 | +4.0% | 3.22M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |